Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: PF-06438179
Biological: Remicade

First Posted Date: 2013-05-01

Last Posted Date: 2014-01-07

Lead Sponsor: Pfizer

Target Recruit Count: 146

Registration Number: NCT01844804

Locations: 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States

A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Palbociclib Formulation Test
Other: Palbociclib Formulation Reference

First Posted Date: 2013-05-01

Last Posted Date: 2013-08-28

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT01844323

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Retrospective Transverse Observational Study Of Previous Study (Initial Protocol, B1811030)

Completed

Conditions: Survival Status at Day 30 After the Last Intake

First Posted Date: 2013-04-25

Last Posted Date: 2014-07-28

Lead Sponsor: Pfizer

Target Recruit Count: 156

Registration Number: NCT01840319

Locations: 🇫🇷
Pfizer Investigational Site, Toulouse, France

Evaluation of the Clinical and Economic Impact of painPRIMER in the Treatment of Low Back Pain in a Primary Care Setting

Terminated

Conditions: Low Back Pain

Interventions: Device: painPREMIER cohort
Other: Control cohort

First Posted Date: 2013-04-23

Last Posted Date: 2015-04-16

Lead Sponsor: Pfizer

Target Recruit Count: 103

Registration Number: NCT01838057

Locations: 🇺🇸
Pfizer Investigational Site, Fayetteville, Georgia, United States

First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-04965842

First Posted Date: 2013-04-18

Last Posted Date: 2014-06-20

Lead Sponsor: Pfizer

Target Recruit Count: 79

Registration Number: NCT01835197

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Post Market Surveillance to Observe Safety of Prevenar13™ in Adults

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: Non-intervention

First Posted Date: 2013-04-17

Last Posted Date: 2017-04-18

Lead Sponsor: Pfizer

Target Recruit Count: 659

Registration Number: NCT01834222

Locations: 🇰🇷
Bundang 21st Clinic, Gyeonggi-do, Korea, Republic of
🇰🇷
Hansarang Internal Medicine Hospital, Busan, South Korea, Korea, Republic of
🇰🇷
Shin Clinic Internal Medicine, Seoul, South Korea, Korea, Republic of

and more 21 locations

Tofacitinib Ointment For Chronic Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis Vulgaris
Psoriasis

Interventions: Drug: placebo ointment (vehicle)
Drug: tofacitinib ointment 10 mg/g
Drug: tofacitinib ointment 20 mg/g

First Posted Date: 2013-04-15

Last Posted Date: 2015-11-25

Lead Sponsor: Pfizer

Target Recruit Count: 476

Registration Number: NCT01831466

Locations: 🇺🇸
MedaPhase Inc., Newnan, Georgia, United States
🇵🇱
NZOZ Solumed, Poznan, Wielkopolskie, Poland
🇨🇦
Dermadvances Research, Winnipeg, Manitoba, Canada

and more 49 locations

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Phase 3

Completed

Conditions: Meningococcal Vaccine

Interventions: Biological: rLP2086
Biological: Havrix (HAV)
Biological: Saline

First Posted Date: 2013-04-12

Last Posted Date: 2016-06-14

Lead Sponsor: Pfizer

Target Recruit Count: 3596

Registration Number: NCT01830855

Locations: 🇺🇸
Holston Medical Group, Kingsport, Tennessee, United States
🇺🇸
Southeastern Pediatrics, Dothan, Alabama, United States
🇺🇸
Arkansas Pediatric Clinic, Little Rock, Arkansas, United States

and more 88 locations

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: PF-02545920

First Posted Date: 2013-04-11

Last Posted Date: 2018-08-20

Lead Sponsor: Pfizer

Target Recruit Count: 37

Registration Number: NCT01829048

Locations: 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States

Sutent Rechallenge In mRCC Patients

Completed

Conditions: Metastatic Renal Cell Carcinoma

First Posted Date: 2013-04-09

Last Posted Date: 2015-04-30

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT01827254

Locations: 🇫🇷
Hopital albert Michalon, Grenoble, Cedex 9, France
🇫🇷
Centre Catalan Urologie Andrologie, Cabestany, France
🇫🇷
clinique de la Louvière, Lille Cedex, France

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy